C4 Therapeutics Files Routine 8-K for Disclosure Compliance

Ticker: CCCC · Form: 8-K · Filed: Jan 11, 2024 · CIK: 1662579

C4 Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyC4 Therapeutics, Inc. (CCCC)
Form Type8-K
Filed DateJan 11, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, compliance, 8-K

TL;DR

**C4 Therapeutics filed a routine 8-K, no major news here.**

AI Summary

C4 Therapeutics, Inc. filed an 8-K on January 11, 2024, to disclose general information, specifically regarding Regulation FD and Financial Statements and Exhibits. This filing is a routine update, indicating no major new events but rather a compliance with disclosure requirements. For investors, this means there are no immediate significant positive or negative catalysts to consider from this specific filing, suggesting a neutral impact on the stock unless further details are revealed in the exhibits.

Why It Matters

This filing is a standard regulatory update, indicating C4 Therapeutics is maintaining compliance with SEC disclosure rules, which is generally a positive sign for corporate governance.

Risk Assessment

Risk Level: low — This 8-K is a standard compliance filing and does not introduce new financial or operational risks.

Analyst Insight

A smart investor would note this as a routine compliance filing and look for the actual content of the 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' if they were included, as this summary only indicates the categories, not the specific details.

Key Numbers

  • 001-39567 — Commission File Number (identifies C4 Therapeutics' registration with the SEC)
  • 47-5617627 — IRS Employer Identification No. (identifies C4 Therapeutics for tax purposes)
  • $0.0001 — par value per share (the nominal value of C4 Therapeutics' common stock)

Key Players & Entities

  • C4 Therapeutics, Inc. (company) — the registrant filing the 8-K
  • Nasdaq Global Select Market (company) — the exchange where C4 Therapeutics' common stock is registered
  • 001-39567 (dollar_amount) — Commission File Number for C4 Therapeutics

FAQ

What is the purpose of C4 Therapeutics' 8-K filing on January 11, 2024?

The 8-K filing by C4 Therapeutics, Inc. on January 11, 2024, is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically covering 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.

What is the trading symbol and exchange for C4 Therapeutics, Inc. common stock?

The trading symbol for C4 Therapeutics, Inc. common stock is 'CCCC', and it is registered on The Nasdaq Global Select Market.

Where is C4 Therapeutics, Inc. incorporated and what is its business address?

C4 Therapeutics, Inc. is incorporated in Delaware, and its principal executive offices are located at 490 Arsenal Way, Suite 120, Watertown, MA 02472.

What is the fiscal year end for C4 Therapeutics, Inc.?

The fiscal year end for C4 Therapeutics, Inc. is December 31.

Does this 8-K filing indicate any pre-commencement communications or soliciting material?

No, the filing explicitly checks 'o' for all options related to written communications pursuant to Rule 425, soliciting material pursuant to Rule 14a-12, pre-commencement communications pursuant to Rule 14d-2(b), and pre-commencement communications pursuant to Rule 13e-4(c), indicating it is not intended to satisfy those obligations simultaneously.

Filing Stats: 905 words · 4 min read · ~3 pages · Grade level 12.8 · Accepted 2024-01-11 07:05:40

Key Financial Figures

  • $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. O n January 11, 2024 , C4 Therapeutics, Inc. (the "Company") posted an investor presentation to its website at https://ir.c4therapeutics.com/events-presentations . A copy of the investor presentation is furnished herewith as Exhibit 99.1. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the Company's expectations regarding the timing and results of the Restructuring; the estimated charges and costs expected to be incurred therewith; the Company's ability to successfully implement its cost-saving initiatives and to capture expected efficiencies; and expectation that the Restructuring will preserve its cash runway into 2027. The use of words such as "anticipate," "believe," "continue," "could," "endeavor," "estimate," "expect," "anticipate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "will" or "would" or the negative of such words or other similar expressions can be used to identify forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. These and other risks and uncertainties are described in additional detail in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K filed February 23, 2023, its Quarterly Reports on Form 10-Q filed on May 4, 2023, August 8, 2023, and November 10, 2023, and its other filings made with the Securities and Exchange Commission from time to time. Although the Company's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this Current Report on Form 8-K speaks only as of the date on which it is made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new informat

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 99.1 Investor presentation of the Company dated January 11, 2024 (furnished herewith) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: January 11, 2024 By: /s/ Kendra R. Adams Kendra R. Adams Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.